Compounded Tirzepatide Online in 2026: The Complete Guide

Compounded tirzepatide is a physician-prescribed, cash-pay path to dual GIP and GLP-1 weight loss treatment. It contains tirzepatide, is prepared by state-licensed compounding pharmacies, and is not FDA-approved as a final product or a generic version of, or interchangeable with, any brand medication. Here is the honest 2026 guide.

Majesta Health Medical TeamMedically Reviewed
Reviewed May 24, 20268 min read

Quick Answer

Compounded tirzepatide is a prescription medication that contains tirzepatide. It is prepared by a state-licensed compounding pharmacy and prescribed by a US-licensed physician for an individual patient. It is not FDA-approved as a final product and is not a generic version of, equivalent to, or interchangeable with any FDA-approved medication. The active pharmaceutical ingredient meets United States Pharmacopeia (USP) standards.

In 2026, compounded tirzepatide ranges from about $299 to $549 per month through reputable US telehealth providers, with the physician consultation, medication, and shipping typically bundled.

What Tirzepatide Actually Does

Tirzepatide is the first dual GIP and GLP-1 receptor agonist approved for use in humans. Unlike semaglutide, which only activates the GLP-1 receptor, tirzepatide activates both the GIP and GLP-1 receptors at the same time.

What this means in practice:

  • Slows gastric emptying. Food stays in your stomach longer, so you feel full sooner and stay full longer.
  • Quiets food noise. The constant background hunger and craving signals get dialed down.
  • Improves insulin sensitivity. Your body uses insulin more efficiently, which is why tirzepatide also works as a diabetes medication.
  • Reduces fat absorption pathways. The GIP component adds a metabolic effect that semaglutide does not have alone.
  • How Compounded Tirzepatide Is Regulated

    Compounded tirzepatide is legal in the United States when done correctly: a US-licensed physician writes a patient-specific prescription with a documented clinical reason, and a state-licensed 503A or 503B compounding pharmacy prepares the medication to USP standards. The finished compounded product is not FDA-approved and is not a generic version of, equivalent to, or interchangeable with any FDA-approved medication. Whether any tirzepatide treatment is appropriate for you, and in which form, is your physician's clinical decision.

    2026 Pricing Reality

    Here is what cash-paying patients actually pay for compounded tirzepatide in 2026:

    *Compounded tirzepatide through US-licensed telehealth (2026):*

  • Henry Meds: $369 to $499 per month depending on plan tier (as of mid-2026; verify current pricing at the provider's site)
  • Majesta Health Performance plan: $339 first month, then $439 per month (physician + medication + shipping)
  • Medvi: $329 first month, then $429 per month
  • Several smaller providers: $299 to $549 per month
  • Note: Hims & Hers and Ro both adjusted their compounded GLP-1 offerings in 2025-2026 and moved away from compounded tirzepatide, so older price lists that include them are out of date.

    *With insurance:*

    Most commercial insurance plans require prior authorization for tirzepatide for weight loss. Many decline coverage unless the patient has type 2 diabetes (in which case Mounjaro is often covered) or specific obesity comorbidities. Compounded tirzepatide is almost never covered. HSA and FSA cards are accepted by most legitimate telehealth platforms.

    What About Clinical Evidence?

    No clinical trial has evaluated compounded tirzepatide itself. There are no published efficacy figures for the compounded preparation, and it should not be assumed to be equally safe or effective as any FDA-approved medication. What that means in practice: your prescribing physician sets your dose, your titration schedule, and realistic expectations based on your medical history and how you respond, and follow-up visits are where progress is actually measured. Weight management outcomes also depend heavily on nutrition, activity, and consistency, not the prescription alone. Individual results vary.

    Safety Profile

    A physician will counsel you on the side effects known for tirzepatide as an ingredient. The compounded preparation is not FDA-approved as a final product and should not be assumed to behave identically to any studied product.

    *Common (mostly first 4 to 8 weeks):*

  • Nausea
  • Diarrhea
  • Decreased appetite
  • Vomiting
  • Constipation
  • Fatigue
  • Injection site reactions
  • These typically fade as your body adjusts and your physician titrates the dose. Slow dose escalation (starting at 2.5 mg, increasing every 4 weeks) reduces side effect burden significantly.

    *Serious but rare (require physician screening):*

  • Pancreatitis
  • Gallbladder problems (gallstones, cholecystitis)
  • Acute kidney injury from severe dehydration secondary to vomiting or diarrhea
  • Diabetic retinopathy worsening in patients with pre-existing diabetic eye disease
  • FDA boxed warning about thyroid C-cell tumors in rodents. Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
  • A legitimate physician reviews your medical history, current medications, thyroid history, and pancreatitis history before prescribing. This is the safety step that should never be skipped, whether you choose compounded or brand-name.

    Who Should Consider Tirzepatide

    Tirzepatide may be the right choice if:

  • You have a BMI of 30 or higher (obesity classification)
  • You have a BMI of 27 to 29 with at least one weight-related condition (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea)
  • You tried semaglutide and the appetite suppression was insufficient at maximum dose
  • You have type 2 diabetes (tirzepatide also improves glycemic control)
  • You want a medication with the strongest published weight-loss data to date
  • You can pay $329 to $549 per month out of pocket for a cash-pay compounded program, or you have insurance coverage for an FDA-approved tirzepatide medication, which may be a better option to discuss with your physician
  • Tirzepatide may not be the right choice if:

  • You have a personal or family history of medullary thyroid carcinoma or MEN2
  • You have a history of pancreatitis
  • You are pregnant, trying to conceive, or breastfeeding
  • You have severe gastroparesis
  • Cost is the primary barrier and a less-aggressive option (semaglutide injection at $179 to $299 first month, or sublingual semaglutide at $179 first month) makes more financial sense for your goals
  • How to Get Compounded Tirzepatide Online Safely

    The legitimate path has five steps:

    1. Real medical questionnaire. A US-licensed telehealth provider collects your medical history, BMI, current medications, and screening data. This takes 2 to 5 minutes. 2. Physician review. A board-certified physician licensed in your state reviews your file, screens for contraindications (thyroid history, pancreatitis history, kidney function, drug interactions), and decides whether tirzepatide is medically appropriate. 3. Prescription. If appropriate, the physician writes a valid prescription specifying your starting dose (usually 2.5 mg weekly) with a titration plan. 4. State-licensed compounding pharmacy. Your prescription is sent to a 503A or 503B compounding pharmacy, ideally NABP-accredited and LegitScript certified, which compounds tirzepatide using active pharmaceutical ingredient that meets United States Pharmacopeia (USP) standards and tests every batch for potency and sterility. 5. Discreet delivery. Your medication ships in plain packaging, temperature-controlled if needed, signature required. Typical delivery is 5 to 7 business days.

    Ongoing care matters. Side effects, dose adjustments, and titration questions come up for almost every patient. Pick a provider that includes ongoing physician messaging in the price, not as a paid add-on.

    Red Flags (Avoid These Sources)

    A price that looks too good usually means the provider is cutting one of the legitimate steps above. Watch for:

  • Sellers offering tirzepatide as "research peptides" or "not for human consumption"
  • Online marketplaces or social-media sellers offering tirzepatide without a prescription
  • Offshore pharmacies shipping directly to US patients without a US physician prescription
  • Telehealth platforms with no named medical director, no published clinical review process, and no clinician licensing transparency
  • Anyone promising specific weight loss results, fake before-and-after photos, or testimonials that look manufactured
  • Pricing under roughly $200 per month for ongoing tirzepatide (suspicious; legitimate cash pricing is $249 to $549 per month in 2026)
  • Sellers who do not disclose that compounded preparations are not FDA-approved as final products
  • None of these are safe paths. They also create real legal risk for the buyer in addition to product quality risk.

    How Compounded Tirzepatide Compares to Semaglutide

    Tirzepatide and semaglutide are different molecules with different mechanisms, and which one fits you is a clinical decision. Your physician weighs your history, tolerability, and goals rather than headline averages.

    Trade-offs:

  • Cost. Tirzepatide is meaningfully more expensive than semaglutide, even compounded. The active pharmaceutical ingredient costs the pharmacy more.
  • Side effect burden. Tirzepatide can produce stronger appetite suppression. For some patients, that means more nausea in early weeks. Slow titration mitigates this.
  • Insurance coverage. FDA-approved weight-management medications are sometimes covered with prior authorization; if your insurance covers one, that may be a better option to discuss with your physician. Compounded preparations are almost never covered.
  • For patients new to GLP-1 medications, many physicians start with semaglutide because it has a longer track record. For patients with a history on semaglutide who plateaued or whose appetite suppression was insufficient, tirzepatide is a logical next step.

    See our tirzepatide vs semaglutide comparison for a deeper look.

    The Bottom Line

    Compounded tirzepatide is a legal, US-licensed-physician path to dual GIP and GLP-1 weight loss treatment in 2026, priced as one bundled monthly cash amount. It contains tirzepatide, and the compounded preparation is not FDA-approved as a final product and is not a generic version of, or interchangeable with, any brand medication. It is prepared at state-licensed compounding pharmacies under a real physician's prescription and is dispensed only to patients with a valid medical evaluation.

    Pricing in 2026 ranges from $299 to $549 per month through legitimate US telehealth platforms, all-in. The choice between compounded and brand-name routes comes down to insurance, your physician's clinical judgment, and your cash budget; brand pricing is published by the manufacturers.

    The most important variable is not whether you pick compounded or brand-name. It is whether the prescribing physician and the dispensing pharmacy are legitimate. A board-certified physician who reviews your medical history and an accredited compounding pharmacy with batch testing are the safety standards that matter most.

    If you are considering tirzepatide and want a physician-reviewed recommendation, start your 2-minute medical assessment at /quiz. A US-licensed physician will review your information, screen for contraindications, and recommend the right plan for you.

    For a fuller picture of the GLP-1 landscape, see our guides on compounded semaglutide, the cheapest semaglutide online in 2026, and every GLP-1 brand and generic available in 2026.


    This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider. Compounded medications are not FDA-approved as final products. Prices reflect typical 2026 US retail and are subject to change. Individual results may vary.

    <!-- striking-distance-injected -->

    Related cost and comparison guides

  • Compounded tirzepatide cost in 2026
  • Frequently Asked Questions

    What is compounded tirzepatide?

    Compounded tirzepatide is a prescription medication prepared by a state-licensed compounding pharmacy using an active pharmaceutical ingredient that meets United States Pharmacopeia (USP) standards. It is not FDA-approved as a final product and is not a generic version of, or interchangeable with, any brand-name medication. Tirzepatide is a dual GIP and GLP-1 receptor agonist, meaning it activates two gut hormone receptors at the same time. The compounded preparation is not FDA-approved as a final product, but the active ingredient meets United States Pharmacopeia (USP) standards, and the medication is prescribed by a US-licensed physician for an individual patient.

    How much does compounded tirzepatide cost online in 2026?

    In 2026, compounded tirzepatide from US-licensed telehealth platforms typically ranges from $299 to $549 per month. Through Majesta Health, our Performance plan is $339 your first month and $439 per month after, with the physician consultation, medication, and discreet shipping included. Brand-name prices and insurance coverage vary widely; current brand pricing is published by the manufacturers.

    Is compounded tirzepatide the same as Mounjaro or Zepbound?

    No. Compounded tirzepatide contains tirzepatide, but it is not the same product as any FDA-approved medication. It is prepared in small batches at state-licensed 503A or 503B compounding pharmacies based on a physician's prescription for an individual patient. It is not FDA-approved as a final product and is not a generic version of, equivalent to, or interchangeable with any brand-name medication, and it should not be assumed to be equally safe or effective.

    Is compounded tirzepatide legal in the United States?

    Yes, when prepared by a state-licensed 503A or 503B compounding pharmacy in response to a valid prescription from a US-licensed physician. Compounding is regulated under sections 503A and 503B of the federal Food, Drug, and Cosmetic Act. State boards of pharmacy oversee 503A pharmacies. Tirzepatide products sold without a prescription, marketed as 'research peptides,' or shipped from offshore pharmacies are not legal.

    How effective is compounded tirzepatide for weight loss?

    No clinical trial has evaluated compounded tirzepatide itself, so there are no published efficacy figures for the compounded preparation, and it should not be assumed to be equally safe or effective as any FDA-approved medication. Your prescribing physician sets your dose and realistic expectations based on your history and response. Real-world results vary by dose, consistency, lifestyle, and individual response.

    What are the side effects of compounded tirzepatide?

    Physicians counsel patients on the side effects known for tirzepatide as an ingredient, while noting that the compounded preparation itself has not been studied in trials and should not be assumed to behave identically. The most common side effects reported for tirzepatide, especially during the first 4 to 8 weeks of treatment, are nausea, diarrhea, decreased appetite, vomiting, constipation, and fatigue. Serious but rare risks include pancreatitis, gallbladder problems, acute kidney injury from dehydration, diabetic retinopathy progression in patients with pre-existing diabetic eye disease, and the FDA boxed warning about thyroid C-cell tumors based on rodent studies. A US-licensed physician screens for these contraindications before prescribing.

    Medically reviewed

    Majesta Health Medical Team

    Clinical Editorial Team

    Majesta Health medical content is written against primary sources (FDA labels, peer-reviewed trials, HHS and CDC publications) and passes a documented compliance review before publication. We are rolling out named physician review with US-licensed clinicians from our partner MD Integrations (MDI): each reviewed article will show the reviewing physician's name, NPI, and review date. MDI is LegitScript certified and SOC 2 Type II accredited.

    Credentials and accreditation
    • US-licensed physicians affiliated with our clinical partner MD Integrations (LegitScript certified, HIPAA, SOC 2 Type II, ISO certified)
    • Board-certified in primary care and obesity medicine
    • Active state medical licensure required for every prescribing clinician
    • Active DEA registration where applicable (note: GLP-1 medications are not controlled substances)
    • Telehealth practice across the states we currently serve through the MD Integrations Medical Services Organization (coverage varies by state; see our states page)
    • Dispensing pharmacy partner: Belmar Pharma Solutions (LegitScript certified, NABP accredited); Majesta prescriptions are dispensed through Belmar's state-licensed 503A compounding pharmacy
    Areas of expertise
    GLP-1 receptor agonist therapy (semaglutide, tirzepatide, liraglutide)Chronic weight managementObesity medicineCompounded medication clinical oversightTelehealth informed consent and patient screening
    Have a question for our medical team? See our full clinical team page or contact support.

    Ready to Reserve Your Spot?

    Join the founding-member waitlist for priority access and locked-in pricing.

    Start Your Assessment